Biw-8962
Phase 2 Portion : Small Cell Lung Cancer(SCLC)
Kyowa Kirin Korea Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
291 Active assets in the Phase 2 Portion : Small Cell Lung Cancer(SCLC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
vx-970 National Cancer Institute (NCI) | Phase 2 | BBB |
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
Veliparib Central European Society for Anticancer Drug Research | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Biw-8962 is also rated in:
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), MesotheliomaDormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →